Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis

Title: Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis
Authors: Balleari E.; Filiberti R. A.; Salvetti C.; Allione B.; Angelucci E.; Bruzzone M.; Calzamiglia T.; Cavaliere M.; Cavalleri M.; Cilloni D.; Clavio M.; Crisa E.; Da Col A.; Danise P.; Pilo F.; Ferrero D.; Finelli C.; Gioia D.; Lemoli R. M.; Masiera E.; Messa E.; Miglino M.; Musto P.; Natalie Oliva E.; Poloni A.; Salvi F.; Sanna A.; Scudeletti M.; Tassara R.; Santini V.
Contributors: Balleari E.; Filiberti R.A.; Salvetti C.; Allione B.; Angelucci E.; Bruzzone M.; Calzamiglia T.; Cavaliere M.; Cavalleri M.; Cilloni D.; Clavio M.; Crisa E.; Da Col A.; Danise P.; Pilo F.; Ferrero D.; Finelli C.; Gioia D.; Lemoli R.M.; Masiera E.; Messa E.; Miglino M.; Musto P.; Natalie Oliva E.; Poloni A.; Salvi F.; Sanna A.; Scudeletti M.; Tassara R.; Santini V.
Publication Year: 2019
Collection: Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto)
Subject Terms: anemia; erythropoietin; myelodysplastic syndromes
Description: Background: Erythropoiesis-stimulating agents effectively improve the hemoglobin levels in a fraction of anemic patients with myelodysplastic syndromes (MDS). Higher doses (HD) of recombinant human erythropoietin (rhEPO) have been proposed to overcome suboptimal response rates observed in MDS patients treated with lower “standard doses” (SD) of rhEPO. However, a direct comparison between the different doses of rhEPO is lacking. Methods: A cohort of 104 MDS patients treated with HD was retrospectively compared to 208 patients treated with SD in a propensity score-matched analysis to evaluate hematological improvement-erythroid (HI-E) rate induced by the different doses of rhEPO. The impact of rhEPO doses on survival and progression to leukemia was also investigated. Results: Overall HI-E rate was 52.6%. No difference was observed between different rhEPO doses (P =.28) in matched cohorts; in a subgroup analysis, transfusion-dependent patients and patients with higher IPSS-R score obtained a higher HI-E rate with HD, although without significant impact on overall survival (OS). Achievement of HI-E resulted in superior OS. At univariate analysis, a higher HI-E rate was observed in transfusion-independent patients (P
Document Type: article in journal/newspaper
Language: English
ISSN: 2045-7634
Relation: info:eu-repo/semantics/altIdentifier/pmid/31657156; info:eu-repo/semantics/altIdentifier/wos/WOS:000492686800001; volume:8; issue:18; firstpage:7567; lastpage:7576; numberofpages:10; journal:CANCER MEDICINE; http://hdl.handle.net/2318/1732950; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85074585399; http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634
DOI: 10.1002/cam4.2638
DOI: 10.1002/(ISSN)2045-7634
Availability: http://hdl.handle.net/2318/1732950; https://doi.org/10.1002/cam4.2638; http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2045-7634
Rights: info:eu-repo/semantics/openAccess
Accession Number: edsbas.AAC31BB
Database: BASE